ViiV Healthcare HIV Treatment Strategy and Dolutegravir

ViiV Healthcare presentation covering the company's vision, operating model, and HIV market position. Key focus on dolutegravir (DTG) portfolio and R&D strategy, delivered by CEO Dominique Limet and Chief Scientific and Medical Officer John Pottage.